{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005944","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.211349+00:00","generated_at":"2026-05-23T06:55:06.935323+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Cocrystal Pharma's Norovirus Antiviral CDI-988 Shows Potent Activity Against Emerging GII.17 Variants","bullets":["CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.","Company plans to initiate a human norovirus challenge study in 2025 for prevention and treatment.","Phase 1 study showed favorable safety and tolerability of CDI-988 in healthy adults.","Norovirus causes ~685 million cases and ~50,000 child deaths annually with $60B societal cost.","No approved antiviral treatments or vaccines for norovirus exist."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005944","json":"https://secwatch.observer/filing/0001641172-25-005944.json","markdown":"https://secwatch.observer/filing/0001641172-25-005944.md","text":"https://secwatch.observer/filing/0001641172-25-005944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/0001641172-25-005944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-23T06:55:06.935323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}